Detail akcie Protalix BioThps Rg online

Business Summary: Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Protalix Biotherapeutics Inc revenues increased from $3.7M to $10.1M. Net loss decreased 21% to $3.6M. Revenues reflect License And Service increase of 66% to $118K. Lower net loss reflects GENERAL AND ADMINISTRATIVE EXPENSES decrease of 16% to $2.6M (expense), FINANCIAL EXPENSES decrease of 98% to $6K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.06 to -$0.05.